Is 5-Amino-1MQ Legal in Europe?
Is 5-Amino-1MQ legal in Europe? It has no EMA authorisation, no novel-food status, and exists in a genuine regulatory vacuum. An honest, source-cited look at what 'legal' really means for this NNMT inhibitor.
5-Amino-1MQ has no marketing authorisation from the European Medicines Agency, no EU novel-food status, and is not scheduled as a narcotic anywhere in Europe. What it does have is a regulatory vacuum — and a vacuum is not a clearance. The honest question is not 'is 5-Amino-1MQ legal' but 'legal for what': handling it as a characterised research reagent may be permissible in many EU member states; using or supplying it for human consumption is not.
5-Amino-1MQ sits in an awkward position that is increasingly familiar in the research-compound space: a molecule of genuine scientific interest, no regulatory framework that straightforwardly addresses it, and a gap between “not explicitly banned” and “cleared for human use” that is far wider than most sources acknowledge. The question “is 5-Amino-1MQ legal in Europe” is not wrong — it is just incomplete. Legality was never a property of the molecule. It is a property of what you intend to do with it.
What is 5-Amino-1MQ, and why does the science matter here?
5-Amino-1MQ — 5-amino-1-methylquinolinium — is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme involved in one-carbon metabolism and the regulation of NAD+ precursor availability. It is not a peptide. Its mechanism is distinct from the peptide and hormone classes that populate most research-compound catalogues, and that distinction matters when considering regulatory classification.
The compound entered the scientific literature in earnest in 2018, when Neelakantan, Vance, Wetzel and colleagues published rodent data showing that selective NNMT inhibition with 5-amino-1MQ reduced body weight and white adipose mass in diet-induced obese mice.3 The experimental model was pre-clinical throughout. There are no published human clinical trials, no Phase I safety data reviewed by any public regulatory body, and no entry in any clinical trial registry. This early-stage context is not a minor caveat — it is load-bearing for every regulatory question that follows, because it means no authority anywhere has had occasion to formally evaluate what 5-amino-1MQ does in human beings.
Is 5-Amino-1MQ approved as a medicine in Europe?
No. The European Medicines Agency has never received a marketing authorisation application for 5-Amino-1MQ, and the compound holds no authorisation in any individual EU member state.1 It has not been classified as a medicine by any regulatory body anywhere in the world. The absence of any regulatory application reflects the compound’s status: it is a research tool at a very early stage of investigation, not a candidate advancing through a formal drug-development pathway.
That absence creates the first and most important point: there is no lawful route by which an EU physician can prescribe 5-Amino-1MQ as a medicine, and no approved therapeutic indication anywhere. This is not a political or procedural technicality — it is the legal baseline from which everything else follows.
Does “not scheduled” mean “cleared”?
This is where the honest answer diverges from the common one. 5-Amino-1MQ is not listed as a scheduled narcotic or psychotropic in the EU or in Spain. That removes one specific legal barrier. It does not remove the others, and it is emphatically not a positive regulatory clearance.
The reason is structural. EU medicines law — built on Directive 2001/83/EC2 — defines a medicinal product in two ways: by presentation (anything presented as treating or preventing disease) and by function (any substance administered to modify physiological functions in humans).2 The by-function definition is a catch-all. It does not require that a compound be explicitly named anywhere. If a substance is offered or used with the purpose of modifying physiology in a human being, it falls within the medicinal product definition regardless of whether it appears on any list, and the legal consequences of supplying an unauthorised medicine apply in full. NNMT inhibition is, by design, a physiological intervention — which is precisely why NNMT is being studied as a metabolic drug target. The regulatory logic follows directly: obscurity in the schedule lists is not the same as absence from the regulatory framework.
| Question | Status under the verified facts |
|---|---|
| EMA marketing authorisation | No — never applied for |
| Approved as a medicine in any country | No |
| Scheduled narcotic or psychotropic (EU / Spain) | No |
| “Not scheduled” = positively cleared for human use | No — by-function medicinal definition still applies |
| Listed in EU Novel Food Catalogue or Union list | No — absent |
| Human clinical trials published | No — rodent and in-vitro only |
| Supply as RUO research reagent | Permissible in much of the EU under that label |
| Supply or use for human consumption | Not permitted |
| Explicitly named on the WADA 2026 Prohibited List | No — but doping status is unsettled (see below) |
What about food supplement status?
A separate regulatory route is sometimes suggested: if a compound is not a medicine, could it be a food supplement? For 5-Amino-1MQ, the answer is no on present facts. The EU operates a Union list of authorised novel foods under Regulation (EU) 2015/2283, administered through the EFSA novel-food process. 5-Amino-1MQ does not appear in the EU Novel Food Catalogue or the Union list.4 No application has been submitted to EFSA. Any sale of this compound as a food ingredient or supplement within the EU would require prior authorisation that does not exist — a separate and additional legal barrier beyond the medicines framework.
5-Amino-1MQ is legal to handle as a research reference material in much of the EU, and there is no lawful route to use it for human consumption anywhere in the Union. Both statements are true at the same time.
Zero public regulatory authorities have reviewed the human safety profile of 5-Amino-1MQ — the entire evidence base is rodent models and cell culture.
Does the legal picture vary across EU member states?
Yes, and that variation matters. Directive 2001/83/EC provides a shared EU architecture, but it is a directive — not a directly applicable regulation — so each member state transposes it into its own national law.2 The result is a common framework with nationally variable enforcement and classification. A compound that circulates freely as a research reagent in one member state may encounter more assertive national medicines-law enforcement in another, particularly once human use enters the frame. This is not a hedge; it is the legal reality of a directive-based system applied to a compound that no national regulator has specifically addressed. Anyone responsible for handling 5-Amino-1MQ in a particular jurisdiction should seek competent legal advice on the national position — a task for a qualified local lawyer, not a general article.
Is 5-Amino-1MQ banned in sport?
The 2026 WADA Prohibited List does not explicitly name 5-Amino-1MQ.5 That is not the same as a clean answer. The S4.4 metabolic modulators category covers a range of mechanisms including AMPK activators, PPARδ agonists, and related metabolic-pathway agents; the category is described in terms of mechanism and effect, not exhaustive named-compound lists.5 NNMT inhibition operates through a related metabolic pathway — modulating NAD+ precursor availability and downstream sirtuin activity — and should evidence of ergogenic use emerge, the S4.4 catch-all could plausibly apply. The Monitoring Programme, which WADA uses to track substances not yet prohibited but under surveillance, is a separate consideration; 5-Amino-1MQ does not appear there either as of the 2026 list, but the absence of a listing should not be read as a positive determination of permissibility. Athletes should treat the doping status of 5-Amino-1MQ as genuinely unresolved and seek a formal ruling from their relevant anti-doping authority before any use.
What does an honest answer concede?
Several things. The regulatory vacuum is real: because no authority has specifically addressed 5-Amino-1MQ, there is no definitive ruling to point to in either direction. That vacuum should not be read as space in which human use is freely permitted — it is, rather, the space in which the broad by-function definition of Directive 2001/83/EC does the most work, precisely because no specific clearance exists.2
The science is genuinely early. A single rodent study, however well-executed, does not establish human safety or efficacy, and the absence of any clinical data means no public body has ever had occasion to review the human risk profile. That absence is itself a risk signal. The temptation to read early pre-clinical data as a proof-of-concept that validates human experimentation should be resisted: the compound may be interesting in a laboratory setting precisely because it has not yet encountered the complexity of human physiology at scale.
The country-by-country variation is a genuine uncertainty, not a rhetorical device. And the doping position is unsettled rather than decided. For a broader orientation to the EU regulatory framework within which these compounds sit, see our regulatory position overview.
Everything Condor Research supplies in this category is a characterised research reference material, sold strictly for research use only.1 It is not an approved or prescribable medicine, it is not intended for human or veterinary use, and nothing here is a recommendation to use any compound in or on a human being. This article is for informational purposes only and is not legal advice; responsibility for knowing and complying with applicable local regulation rests with the purchaser. The distinction between a regulated, approved medicine and an RUO reference material is not a formality — it is the entire legal and scientific basis on which legitimate supply rests.
Research Use Only. This material is supplied strictly as a characterised reference reagent for in-vitro and laboratory research. It is not an approved medicine, is not for human or veterinary use, and nothing above is medical or legal advice. — Condor Research · Scientific desk
- 5-Amino-1MQ is a small-molecule NNMT inhibitor studied only in rodent and in-vitro models; no human clinical trials have been conducted and no public authority has reviewed its safety in humans.
- It holds no EMA marketing authorisation and has not been classified as a medicine by any regulatory body anywhere in the world.
- It is absent from the EU Novel Food Catalogue and Union list; any use as a food ingredient would require novel-food authorisation under Regulation (EU) 2015/2283, which no applicant has pursued.
- It is not a scheduled narcotic in the EU or Spain, but "not scheduled" is not a positive clearance — the medicinal product by function catch-all in Directive 2001/83/EC can still apply if the compound is presented or used to modify physiological functions in humans.
- Its doping status under WADA rules is genuinely unsettled: not explicitly named on the 2026 Prohibited List, but the S4.4 metabolic modulators category covers compound classes that could in principle encompass NNMT inhibitors if ergogenic evidence emerged. Athletes should treat the position as unresolved.
Is 5-Amino-1MQ approved as a medicine anywhere in the EU?
No. It has no marketing authorisation from the European Medicines Agency and is not approved in any EU member state, so no EU physician can lawfully prescribe it. It is supplied in Europe only as a research-use-only reference material, not as an approved drug.
Does "not scheduled" mean it is legal to use?
Not for human use. Being absent from narcotic or psychotropic schedules removes one specific barrier, but Directive 2001/83/EC defines a medicinal product by function as well as by presentation. A compound intended to modify physiological functions in humans falls within the medicines framework regardless of scheduling status, so supply for human use without authorisation remains impermissible.
Is 5-Amino-1MQ a novel food in the EU?
No. It does not appear in the EU Novel Food Catalogue or the Union list of authorised novel foods. Any commercial use as a food ingredient would require prior novel-food authorisation under Regulation (EU) 2015/2283, which no applicant has sought.
Is the science settled enough to know whether it works?
No. All published data comes from rodent models and in-vitro cell studies. There are no human clinical trials, and no public authority has reviewed the safety or efficacy of 5-Amino-1MQ in humans. The absence of a safety assessment is itself a risk flag, not a neutral baseline.
Is 5-Amino-1MQ banned in sport under WADA rules?
It is not explicitly named on the WADA 2026 Prohibited List. However, the S4.4 metabolic modulators category is mechanism-based and broad; if ergogenic use evidence were to emerge, an NNMT inhibitor could in principle be captured within it. Athletes should not treat the absence of an explicit listing as permission, and should seek a formal ruling from their anti-doping authority.